Last updated 17 months ago

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

385 patients around the world
Available in Argentina, United States, Brazil, Spain
Kartos Therapeutics, Inc.
4Research sites
385Patients around the world
This study is for people with
Myeloproliferative syndromes
Myelofibrosis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Sanatorio de la Mujer - Rosario
Recruiting
San Luis 2493, Rosario, Santa Fe
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Instituto Cardiovascular San Luis
Recruiting
Rivadavia 1059, San Luis
Hospital Privado de Córdoba
Recruiting
Naciones Unidas 346, Córdoba
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy